Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Albumin-bound and water-soluble toxins represent a broad category of metabolic waste products that accumulate in the blood due to impaired renal or hepatic excretory functions. Water-soluble toxins, such as urea and creatinine, are small molecules that are typically cleared efficiently by conventional hemodialysis (Vanholder et al., 2003, PMID: 12853718). In contrast, albumin-bound toxins, including indoxyl sulfate and p-cresyl sulfate, are characterized by high affinity for serum albumin, which limits their removal via standard dialysis membranes and leads to systemic accumulation (Duranton et al., 2012, PMID: 22677554). These toxins are not traditional drug targets like receptors or enzymes; rather, they are pathological substrates whose removal is the primary goal of renal replacement therapies and certain oral adsorbents. High levels of these substances are strongly associated with the progression of chronic kidney disease (CKD), cardiovascular complications, and uremic syndrome (Lin et al., 2011, PMID: 21734084). Pharmacological interventions like AST-120 (Kremezin) aim to sequester these toxins in the gastrointestinal tract to prevent their absorption into the bloodstream (Schulman et al., 2015, PMID: 25341981). In liver failure, albumin-bound toxins like bilirubin and bile acids contribute to hepatic encephalopathy and systemic organ dysfunction (Stange, 2014, PMID: 25231724).
Removal from systemic circulation via extracorporeal clearance (dialysis/adsorption) or intestinal sequestration to prevent systemic accumulation (Vanholder et al., 2003, PMID: 12853718).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Albumin-bound and water-soluble uremic toxins.